Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.86 |
| ▸ | TSHR | P16473 | 2/20 | 0.86 |
| ▸ | LMNA | P02545 | 2/20 | 0.86 |
| ▸ | MLNR | O43193 | 2/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.86 |
| ▸ | ALB | P02768 | 1/20 | 0.86 |
| ▸ | CNR1 | P21554 | 1/20 | 0.86 |
| ▸ | HTR2A | P28223 | 1/20 | 0.86 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.86 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.82 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | AR | P10275 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL11340609 | 1.00 | CYP3A4 (0.86) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL11340606 | 1.00 | CYP3A4 (0.86) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL536998 | 1.00 | CYP3A4 (0.86) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL29116300 | 1.00 | CYP3A4 (0.86) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL10899622 | 0.99 | CYP3A4 (0.84) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL10899617 | 0.99 | CYP3A4 (0.84) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL7056963 | 0.95 | CYP3A4 (0.93) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL7056958 | 0.95 | CYP3A4 (0.93) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL10897935 | 0.94 | CYP3A4 (0.83) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL9487690 | 0.94 | CYP3A4 (0.94) | CYP3A4KCNH2ABCB1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5071 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228841-A1 | COMPOSITIONS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | APTORUM THERAPEUTICS LTD (HK) | 2025-07-17 | — | — | US | claimed |
| US-12285471-B2 | Methods for treating pulmonary disease using inter-alpha inhibitor proteins | PROTHERA BIOLOGICS, INC. (US) | 2025-04-29 | — | — | US | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| CN-119548460-A | Erythromycin stearate nano micelle oral liquid preparation and preparation method thereof | 神威药业集团有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-118873548-A | Anti-liver cancer cell preparation and application thereof | 新乡医学院 | 2024-11-01 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| EP-4374848-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| US-20240122859-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | NOKHA TRADING LLP (IN) | 2024-04-18 | — | — | US | claimed |
| EP-0277741-A1 | Spherical granules having core and their production | Takeda Chemical Industries, Ltd. (JP) | 1988-08-10 | — | — | EP | claimed |
| EP-0109102-B1 | STORAGE STABLE TOPICAL PHARMACEUTICAL COMPOSITION INCLUDING NITROGEN-CONTAINING STABILIZERS | THE PROCTER & GAMBLE COMPANY (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0109102-A2 | Storage stable topical pharmaceutical composition including nitrogen-containing stabilizers | THE PROCTER & GAMBLE COMPANY (US) | 1984-05-23 | — | — | EP | claimed |
| EP-0027286-B1 | ANTI-ACNE COMPOSITION COMPRISING DIISOPROPYL SEBACATE | THE PROCTER & GAMBLE COMPANY (US) | 1984-02-08 | — | — | EP | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-4299826-A | TOPICAL APPLICATION OF ERYTHROMYCIN OR DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1981-11-10 | — | — | US | claimed |
| EP-0001871-B1 | AN ERYTHROMYCIN COMPOUND, A PROCESS FOR PREPARING THE COMPOUND AND COMPOSITIONS CONTAINING THE COMPOUND USEFUL IN THE TREATMENT OF ACNE | THE PROCTER & GAMBLE COMPANY (US) | 1981-07-29 | — | — | EP | claimed |
| EP-0027286-A2 | Anti-acne composition comprising diisopropyl sebacate | THE PROCTER & GAMBLE COMPANY (US) | 1981-04-22 | — | — | EP | claimed |
| US-4261982-A | ZINC ERYTHROMYCIN FOR ACNE | THE PROCTER & GAMBLE COMPANY (US) | 1981-04-14 | — | — | US | claimed |
| EP-0001871-A1 | An erythromycin compound, a process for preparing the compound and compositions containing the compound useful in the treatment of acne | THE PROCTER & GAMBLE COMPANY (US) | 1979-05-16 | — | — | EP | claimed |